Robert W. Baird downgraded shares of Leap Therapeutics (NASDAQ:LPTX - Free Report) from an outperform rating to a neutral rating in a research note published on Wednesday morning, Marketbeat Ratings reports. Robert W. Baird currently has $1.25 price objective on the stock, down from their prior price objective of $9.00.
Separately, HC Wainwright reaffirmed a "buy" rating and set a $5.50 price target on shares of Leap Therapeutics in a research report on Thursday, January 16th.
Check Out Our Latest Stock Report on Leap Therapeutics
Leap Therapeutics Price Performance
Shares of LPTX stock traded up $0.04 on Wednesday, hitting $0.56. The stock had a trading volume of 1,101,612 shares, compared to its average volume of 1,245,543. Leap Therapeutics has a 12-month low of $0.51 and a 12-month high of $4.79. The stock has a market cap of $21.46 million, a price-to-earnings ratio of -0.29 and a beta of 0.17. The business has a 50 day moving average of $2.74 and a 200 day moving average of $2.73.
Institutional Trading of Leap Therapeutics
Hedge funds have recently made changes to their positions in the company. Marshall Wace LLP raised its holdings in Leap Therapeutics by 268.2% during the 2nd quarter. Marshall Wace LLP now owns 79,758 shares of the company's stock valued at $156,000 after acquiring an additional 58,094 shares during the period. Key Client Fiduciary Advisors LLC grew its position in shares of Leap Therapeutics by 13.0% in the third quarter. Key Client Fiduciary Advisors LLC now owns 321,923 shares of the company's stock valued at $827,000 after purchasing an additional 37,067 shares in the last quarter. Simplify Asset Management Inc. raised its stake in shares of Leap Therapeutics by 67.4% during the 3rd quarter. Simplify Asset Management Inc. now owns 1,056,895 shares of the company's stock valued at $2,716,000 after purchasing an additional 425,626 shares during the period. Valence8 US LP purchased a new stake in Leap Therapeutics during the 3rd quarter worth about $48,000. Finally, HighTower Advisors LLC purchased a new stake in Leap Therapeutics during the 3rd quarter worth about $65,000. 30.46% of the stock is currently owned by institutional investors.
About Leap Therapeutics
(
Get Free Report)
Leap Therapeutics, Inc, a biopharmaceutical company, acquires and develops antibody therapies for the treatment of cancer. Its lead product candidates include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in multiple ongoing clinical trials for treating esophagogastric and gynecologic cancers; and FL-301, a monoclonal antibody that targets cells that express Claudin18.2 on their cell surface and is in phase II clinical trial, as well as two preclinical antibody programs, FL-302 and FL-501.
Featured Articles
Before you consider Leap Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Leap Therapeutics wasn't on the list.
While Leap Therapeutics currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
